-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMG-193 in Metastatic Biliary Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMG-193 in Metastatic Biliary Tract Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMG-193 in Metastatic Biliary Tract Cancer Drug Details: AMG-193 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tazemetostat Hydrobromide in Central Nervous System (CNS) Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tazemetostat Hydrobromide in Central Nervous System (CNS) Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tazemetostat Hydrobromide in Central Nervous System (CNS) Cancer...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MP-0310 in Transitional Cell Cancer (Urothelial Cell Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MP-0310 in Transitional Cell Cancer (Urothelial Cell Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MP-0310 in Transitional Cell Cancer (Urothelial Cell Cancer)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dostarlimab in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dostarlimab in Fallopian Tube Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dostarlimab in Fallopian Tube Cancer Drug Details: Dostarlimab (Jemperli) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MP-0310 in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MP-0310 in Breast Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MP-0310 in Breast Cancer Drug Details: MP-0310 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MP-0310 in Cutaneous Squamous Cell Carcinoma (cSCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MP-0310 in Cutaneous Squamous Cell Carcinoma (cSCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MP-0310 in Cutaneous Squamous Cell Carcinoma (cSCC) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Selinexor in Refractory Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Selinexor in Refractory Acute Myeloid Leukemia Drug Details: Selinexor (Xpovio, Nexpovio) is an antineoplastic agent....